Real-world safety, dose reduction determinants, and effectiveness of first-line osimertinib in EGFR-mutated non-small-cell lung cancer: a single-center retrospective cohort study

International Journal of Lung Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles